CalciMedica 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   3 Trials   82 News 


12»
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment open:  KOURAGE: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk" (clinicaltrials.gov) -  Jun 12, 2024   
    P2,  N=150, Recruiting, 
    The novel combination of CM4620 with galactose synergistically targets complementary pathological mechanisms of AP. Not yet recruiting --> Recruiting
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Journal:  Vulnerability of Store-Operated Calcium Entry to Inhibitors and Microenvironment in Cells of Different Breast Cancer Subtypes. (Pubmed Central) -  Mar 28, 2024   
    We have observed that the SOCE inhibitors Leflunomide and Teriflunomide suppress SOCE in the triple-negative BC cell line MDA-MB-231, but not in the luminal A BC cell line MCF-7...In addition, the oxygen scavenger sodium dithionide also affects SOCE, stimulating it in MDA-MB-231 cells but inhibiting in MCF-7 cells. Overall, our data highlight the importance of considering the different sensitivities of various BC cell types to inhibitors and to microenvironmental factors such as hypoxia and acidification when developing targeted drugs.
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    SERUM PROTEOMICS REVEALS THAT THE ORAI1 INHIBITOR AUXORA MAY PROVIDE BENEFITS IN SEVERE ACUTE PANCREATITIS SIMILAR TO THOSE SEEN IN COVID-19 PNEUMONIA (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_1043;    
    P2
    In COVID-19 pneumonia patients, Auxora significantly increased proteins reflecting improved liver function and lipid metabolism, and decreased proteins that mediate coagulopathy, which were previously found increased in cohorts of patients with severe AP and systemic inflammation. The results suggest that treatment with Auxora in patients with AP may offer beneficial clinical outcomes like those seen in patients with severe COVID-19 pneumonia.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Auxora (zegocractin) / CalciMedica
    Review, Journal:  Trends and recent developments in pharmacotherapy of acute pancreatitis. (Pubmed Central) -  Apr 18, 2023   
    However, challenges for exploring targeted treatment approaches include disease complexity, timing of therapeutic intervention, and establishing appropriate clinical endpoints. Understanding the role of specific biomarkers may help in identifying appropriate targets for drug discovery and facilitate determining relevant clinical study endpoints to monitor disease severity and progression, thereby aiding in design of more precise therapies with improved clinical outcomes.
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion date, Trial primary completion date:  CRSPA: Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase (clinicaltrials.gov) -  Mar 24, 2023   
    P1/2,  N=42, Recruiting, 
    Understanding the role of specific biomarkers may help in identifying appropriate targets for drug discovery and facilitate determining relevant clinical study endpoints to monitor disease severity and progression, thereby aiding in design of more precise therapies with improved clinical outcomes. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Journal:  Regulation of neuropathic pain by microglial Orai1 channels. (Pubmed Central) -  Jan 28, 2023   
    Unexpectedly, these protective effects were not seen in female mice, revealing sexual dimorphism in Orai1 regulation of microglial reactivity and hyperalgesia. Together, these findings indicate that Orai1 channels are key regulators of the sexually dimorphic role of microglia for the neuroinflammation that underlies neuropathic pain.
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion date, Trial primary completion date:  CARPO: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS (clinicaltrials.gov) -  Sep 19, 2022   
    P2,  N=216, Recruiting, 
    More large-scale RCTs are still needed to confirm the results of this study. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion, Enrollment change, Trial completion date:  A Study of Auxora in Patients With Critical COVID-19 Pneumonia (clinicaltrials.gov) -  Aug 18, 2022   
    P2,  N=9, Completed, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Active, not recruiting --> Completed | N=36 --> 9 | Trial completion date: Jun 2022 --> Nov 2021
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion date, Trial primary completion date:  CARPO: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS (clinicaltrials.gov) -  May 23, 2022   
    P2,  N=216, Recruiting, 
    Active, not recruiting --> Completed | N=36 --> 9 | Trial completion date: Jun 2022 --> Nov 2021 Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment closed:  A Study of Auxora in Patients With Critical COVID-19 Pneumonia (clinicaltrials.gov) -  May 12, 2022   
    P2,  N=36, Active, not recruiting, 
    Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Recruiting --> Active, not recruiting
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion date, Trial primary completion date:  CARPO: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS (clinicaltrials.gov) -  Mar 24, 2022   
    P2,  N=216, Recruiting, 
    N=240 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Oct 2022 --> Jun 2023 | Trial primary completion date: Oct 2022 --> Jun 2023
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion date, Trial primary completion date:  A Study of Auxora in Patients With Critical COVID-19 Pneumonia (clinicaltrials.gov) -  Mar 10, 2022   
    P2,  N=36, Recruiting, 
    The S1-elicited Ca signals we have observed in the pancreatic stellate cells and endogenous macrophages may play an important part in the development of the inflammatory process. Trial completion date: Oct 2021 --> Jun 2022 | Trial primary completion date: Sep 2021 --> May 2022
  • ||||||||||  Auxora (CM4620) / CalciMedica
    Clinical, Journal:  Orai1-STIM1 Regulates Increased Ca Mobilization, Leading to Contractile Duchenne Muscular Dystrophy Phenotypes in Patient-Derived Induced Pluripotent Stem Cells. (Pubmed Central) -  Nov 29, 2021   
    In this study, we utilized DMD patient-derived induced pluripotent stem cells (iPSCs) to differentiate myotubes using doxycycline-inducible MyoD overexpression, and searched for a target molecule that mediates dystrophin deficiency-dependent Ca overload using commercially available chemicals and siRNAs...These findings were further confirmed by demonstrating that STIM1-Orai1 inhibitors, CM4620, AnCoA4, and GSK797A, prevented Ca overload in dystrophic myotubes...In conclusion, SOCs are major contributors to dystrophin deficiency-dependent Ca overload through STIM1-Orai1 as molecular mediators. Modulating STIM1-Orai1 activity was effective in ameliorating the decline in contractile performance in DMD.
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion date, Trial primary completion date:  A Study of Auxora in Patients With Critical COVID-19 Pneumonia (clinicaltrials.gov) -  Aug 18, 2021   
    P2,  N=36, Recruiting, 
    Modulating STIM1-Orai1 activity was effective in ameliorating the decline in contractile performance in DMD. Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: May 2021 --> Sep 2021
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial completion:  CARDEA: A Study of Auxora in Patients With Severe COVID-19 Pneumonia (clinicaltrials.gov) -  Aug 3, 2021   
    P2,  N=284, Completed, 
    Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: May 2021 --> Sep 2021 Recruiting --> Completed
  • ||||||||||  CM3457 / CalciMedica
    Journal:  Biochemical Profiling for Antioxidant and Therapeutic Potential of Pakistani Chickpea (Cicer arietinum L.) Genetic Resource. (Pubmed Central) -  May 1, 2021   
    In other biochemical parameters, the highest seed total oxidant status (TOS) (356 ± 17.50 μM/g s. wt.) was detected in CM3457/91 (desi); malondialdehyde (MDA) content (295.74 ± 3.097 uM/g s. wt.) was observed in CM-2008 (kabuli), and total antioxidant capacity (TAC) (8.36 ± 0.082 μM/g s. wt.) was found in CM-72 (desi)...For seed therapeutic potential, the highest seed α-amylase inhibition (82.33 ± 8.06%) was observed in CM-88 (desi), while WH-1, WH-6, and ICCV-96030 (desi) depicted the highest value for seed anti-inflammatory potential (78.88 ± 0.55%). Genotypes with the highest antioxidant and therapeutic potential can be utilized as a natural antioxidant source and in breeding programs aimed at improving these traits in new breeding lines.
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Trial primary completion date:  CARDEA: A Study of Auxora in Patients With Severe COVID-19 Pneumonia (clinicaltrials.gov) -  Apr 23, 2021   
    P2,  N=346, Recruiting, 
    Genotypes with the highest antioxidant and therapeutic potential can be utilized as a natural antioxidant source and in breeding programs aimed at improving these traits in new breeding lines. Trial primary completion date: Apr 2021 --> Jul 2021
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment open, Trial completion date, Trial primary completion date:  CARPO: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS (clinicaltrials.gov) -  Mar 26, 2021   
    P2,  N=216, Recruiting, 
    Trial primary completion date: Apr 2021 --> Jul 2021 Not yet recruiting --> Recruiting | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2022 --> Aug 2022
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment open:  A Study of Auxora in Patients With Critical COVID-19 Pneumonia (clinicaltrials.gov) -  Mar 12, 2021   
    P2,  N=36, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2022 --> Aug 2022 Not yet recruiting --> Recruiting
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment open:  CARDEA: A Study of Auxora in Patients With Severe COVID-19 Pneumonia (clinicaltrials.gov) -  Aug 18, 2020   
    P2,  N=400, Recruiting, 
    Using CM4620, we show that SOCE via STIM1/Orai complexes promotes activation and fibroinflammatory gene expression within pancreatic stellate cells. Suspended --> Recruiting
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment change, Trial completion date, Trial suspension, Trial primary completion date:  CARDEA: A Study of Auxora in Patients With Severe COVID-19 Pneumonia (clinicaltrials.gov) -  Jul 17, 2020   
    P2,  N=400, Suspended, 
    Active, not recruiting --> Completed N=120 --> 400 | Trial completion date: Sep 2020 --> Apr 2021 | Recruiting --> Suspended | Trial primary completion date: Jul 2020 --> Mar 2021
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment change:  CARDEA: A Study of Auxora in Patients With Severe COVID-19 Pneumonia (clinicaltrials.gov) -  May 8, 2020   
    P2,  N=120, Recruiting, 
    N=120 --> 400 | Trial completion date: Sep 2020 --> Apr 2021 | Recruiting --> Suspended | Trial primary completion date: Jul 2020 --> Mar 2021 N=60 --> 120
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Enrollment open:  CRSPA: Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase (clinicaltrials.gov) -  Feb 7, 2020   
    P1/2,  N=42, Recruiting, 
    Recruiting --> Active, not recruiting | N=160 --> 56 | Trial primary completion date: Mar 2021 --> Dec 2020 Not yet recruiting --> Recruiting